Category: 3. Business

Firm News  |  January 8, 2026

---

Gibson Dunn is advising Jefferies LLC as lead financial advisor to Ventyx Biosciences, Inc. on Ventyx Biosciences’ approximately $1.2 billion sale to Eli Lilly and Company.

The Gibson Dunn corporate team is led by partners Ryan Murr and Sebastian Fain and includes associates Ashley Whittington and Muriel Hague.

Summary

Cambodia is not alone in facing capacity limitations in the production and timely release of key official statistics needed for data-driven policy decisions. This paper demonstrates that combining satellite-derived indicators (e.g., nighttime lights, NO₂ emissions, vegetation indices) with traditional high-frequency indicators in a machine learning framework significantly improves the accuracy of GDP nowcasts. Moreover, satellite data enables closer examination of subnational patterns, providing granular, near-real-time insights into economic activity. These findings highlight the potential of non-traditional approaches to complement conventional methods and strengthen macroeconomic surveillance in data-scarce environments.

Subject: Agricultural sector, Economic forecasting, Economic sectors, Health

Keywords: Agricultural sector, big data, machine learning, non-traditional data, nowcast, nowcasting, random forest, satellite, satellite data

TransUnion’s (NYSE:TRU) revised mortgage pricing model, which was announced Oct 17, 2025, went live last week. At the center of this new model is VantageScore® 4.0, which delivers three critical benefits:

·       Greater access to loans for qualified homebuyers,

·       Lower costs and more certain prices for lenders and homebuyers,

·       Protection of the safety and soundness of the U.S. mortgage market and economy.

“Consumers deserve a safe and cost-effective mortgage market and VantageScore supports these goals. We are proud to now offer VantageScore 4.0 for mortgage lending, as we have done for years for auto and card lending,” said Chris Cartwright, President and CEO of TransUnion. “VantageScore 4.0, combined with TransUnion, delivers unmatched predictive power as it leverages up to 30 months of trended credit data, along with rental and utility tradelines.

To accelerate adoption of VantageScore, TransUnion is offering VantageScore 4.0 for $4 per score in 2026, representing a 60% discount compared to a FICO score. This pricing enables lenders to keep underwriting costs flat compared to 2025, offering substantial savings for mortgage lenders and consumers alike. TransUnion is actively working with lenders, resellers and GSEs to drive adoption of this new, lower-cost, consumer-friendly option.

 

 

 

 

 

 

 

 

 

For decades, the mortgage industry has been limited by FICO’s monopoly, restricting lending choice and driving costs higher. FICO’s recent royalty hikes – over 100% for 2026 and more than 1600% over the last four years – are the primary driver of rising mortgage lending data costs. TransUnion’s approach of bundling great credit data with VantageScore 4.0 materially reduces prices and enables lenders to effectively manage their businesses without dramatic annual score price increases.

TransUnion’s market leading credit data is a foundation for safe underwriting, anchoring credit scores with the proven accuracy, fairness and reliability needed to keep the world’s largest mortgage market running safely and efficiently.

Learn more about how TransUnion is powering a stronger, safer and more affordable mortgage market.

 Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of TransUnion’s management. Actual results may differ materially from those described in the forward-looking statements. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include information concerning possible or assumed future results of operations, events or developments, including statements relating to the pricing strategies, potential benefits and value propositions of product offerings of TransUnion and our competitors.  We believe these forward-looking statements are reasonable as and when made. However, forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations. These risks and uncertainties include, but are not limited to, those risks described in our Annual Report on Form 10-K for the year ended December 31, 2024, and any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, which are filed with the SEC and available on TransUnion’s website. You should evaluate all forward-looking statements made in this press release in the context of these risks and uncertainties. As a result of such risks and uncertainties, we urge you not to place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release. We undertake no obligation to publicly release the result of any revisions to these forward-looking statements to reflect the impact of events or circumstances that may arise after the date of this press release.

About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world. http://www.transunion.com/business

 

Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions

DUBLIN, Jan. 8, 2026 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026.

Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc., where he served as chief operating and commercial officer. In that role, he directed corporate strategy including the successful sale of Chimerix to Jazz. In addition to leading the transaction process and alliance management at Chimerix, he helped navigate a complex regulatory environment leading to successful U.S. approval and launch of the first approved therapy for H3K27M-mutant diffuse midline glioma affecting approximately 2,000 children and young adults in the U.S. annually. He brings more than 25 years of experience in the pharmaceutical industry leading sales and marketing, business development, operations, and has held multiple C-suite positions across various organizations. In his role as chief business officer, he will lead execution of corporate development initiatives and drive strategic partnerships for the company.

“Tom is an exceptional leader with more than 25 years in the pharmaceutical industry and a proven record of driving strategic transactions,” said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. “He combines a passion for patients with deep commercial, operational, and corporate development expertise, having led over $2 billion in business development deals in the past five years. Tom played a pivotal role in the approval and launch of Modeyso™ (dordaviprone), the first treatment for an ultra-rare, aggressive brain tumor affecting primarily children and young adults. His commitment to patients who previously had no options is truly inspiring. I look forward to working with Tom in this new capacity to strengthen our corporate development capabilities and continue bringing innovative medicines to Jazz’s portfolio that transform lives.”

“I am honored to take on this new role of chief business officer at Jazz,” said Mr. Riga. “I’ve been impressed by the strength and vision of Jazz’s leadership team and look forward to advancing the company through innovative strategic transactions that leverage the existing expertise and capabilities of the company. Together, we will continue to build on our proven corporate development engine to deliver shareholder value and, most importantly, make a meaningful impact for patients with unmet medical need.”

About Jazz Pharmaceuticals 
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:
Jazz Media Contact:Kristin BhavnaniHead of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

Jazz Investor Contact:Jack SpinksExecutive Director, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com 
Ireland +353 1 634 3211
U.S. +1 650 496 2717

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-appoints-thomas-riga-as-chief-business-officer-302656729.html

SOURCE Jazz Pharmaceuticals plc